{"id":489193,"date":"2021-05-06T09:08:17","date_gmt":"2021-05-06T13:08:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/"},"modified":"2021-05-06T09:08:17","modified_gmt":"2021-05-06T13:08:17","slug":"genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/","title":{"rendered":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer"},"content":{"rendered":"

<\/p>\n

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer<\/b><\/p>\n

Amendment to existing worldwide, exclusive license agreement expands Genprex\u2019s oncology franchise <\/i><\/p>\n

Newly licensed technologies include use of Genprex\u2019s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy<\/i><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–Genprex, Inc.<\/a> (\u201cGenprex\u201d or the \u201cCompany\u201d) (Nasdaq: GNPX<\/a>), a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, today announced that the Company and a major cancer research center in Houston, Texas, in March 2021, entered into an amendment (the \u201cAmendment\u201d) to their May 2020 License Agreement (the \u201cLicense Agreement\u201d) to grant to Genprex an exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology (\u201cNewly Licensed IP\u201d). The Newly Licensed IP includes methods for treating non-small cell lung cancer (NSCLC) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies, in patients who are predicted to be responsive to TUSC2 therapy. A TUSC2 gene-expressing plasmid is the active agent in REQORSA\u2122 immunogene therapy, Genprex\u2019s lead drug candidate.\n<\/p>\n

\n\u201cWe are pleased to continue optimizing and expanding our world-class intellectual property portfolio with the addition of these technologies,\u201d said Rodney Varner, President and Chief Executive Officer of Genprex. \u201cThese new technologies further add to our arsenal of combination therapies for REQORSA, and may enable us to improve patient outcomes through the advancement of multiple therapeutic approaches.\u201d\n<\/p>\n

About Genprex, Inc.<\/b><\/p>\n

\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex\u2019s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company\u2019s lead product candidate, REQORSA\u2122 (quaratusugene ozeplasmid<\/i>), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca\u2019s Tagrisso\u00ae (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. <\/i><\/p>\n

\nThe Company is preparing to initiate its Acclaim-1 and Acclaim-2 clinical trials for the treatment of NSCLC. Acclaim-1 is an open-label, multi-center Phase 1\/2 clinical trial that combines REQORSA with AstraZeneca\u2019s Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. The Acclaim-2 clinical trial will combine REQORSA with Merck & Co\u2019s Keytruda for late stage NSCLC patients whose disease progressed after treatment with Keytruda.\n<\/p>\n

\nFor more information, please visit the Company\u2019s web site at www.genprex.com<\/a> or follow Genprex on Twitter<\/a>, Facebook<\/a> and LinkedIn<\/a>.\n<\/p>\n

Cautionary Language Concerning Forward-Looking Statements <\/b><\/p>\n

\nStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex\u2019s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under \u201cItem 1A \u2013 Risk Factors\u201d in Genprex\u2019s Annual Report on Form 10-K.\n<\/p>\n

\nBecause forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex\u2019s clinical trials and regulatory approvals; the effect of Genprex\u2019s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex\u2019s future growth and financial status; Genprex\u2019s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex\u2019s intellectual property and licenses.\n<\/p>\n

\nThese forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210506005306\/en\/<\/a><\/span><\/p>\n

Genprex, Inc.
\n<\/b>
(877) 774-GNPX (4679)\n<\/p>\n

Investor Relations
\n<\/b>
GNPX Investor Relations
\n
(877) 774-GNPX (4679) ext. #2
\n
investors@genprex.com<\/a><\/p>\n

Media Contact
\n<\/b>
Genprex Media Relations
\n
Kalyn Dabbs
\n
(877) 774-GNPX (4679) ext. #3
\n
media@genprex.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Diabetes Research Pharmaceutical Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Amendment to existing worldwide, exclusive license agreement expands Genprex\u2019s oncology franchise Newly licensed technologies include use of Genprex\u2019s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, today announced that the Company and a major cancer research center in Houston, Texas, in March 2021, entered into an amendment (the \u201cAmendment\u201d) to their May 2020 License Agreement (the \u201cLicense Agreement\u201d) to grant to Genprex an exclusive worldwide license to an additional portfolio of … <\/p>\n

Continue reading “Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-489193","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGenprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Amendment to existing worldwide, exclusive license agreement expands Genprex\u2019s oncology franchise Newly licensed technologies include use of Genprex\u2019s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, today announced that the Company and a major cancer research center in Houston, Texas, in March 2021, entered into an amendment (the \u201cAmendment\u201d) to their May 2020 License Agreement (the \u201cLicense Agreement\u201d) to grant to Genprex an exclusive worldwide license to an additional portfolio of … Continue reading "Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-06T13:08:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer\",\"datePublished\":\"2021-05-06T13:08:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/\"},\"wordCount\":957,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/\",\"name\":\"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-05-06T13:08:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk","og_description":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Amendment to existing worldwide, exclusive license agreement expands Genprex\u2019s oncology franchise Newly licensed technologies include use of Genprex\u2019s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy AUSTIN, Texas–(BUSINESS WIRE)–Genprex, Inc. (\u201cGenprex\u201d or the \u201cCompany\u201d) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, today announced that the Company and a major cancer research center in Houston, Texas, in March 2021, entered into an amendment (the \u201cAmendment\u201d) to their May 2020 License Agreement (the \u201cLicense Agreement\u201d) to grant to Genprex an exclusive worldwide license to an additional portfolio of … Continue reading \"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-06T13:08:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer","datePublished":"2021-05-06T13:08:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/"},"wordCount":957,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/","name":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-05-06T13:08:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210506005306r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/489193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=489193"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/489193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=489193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=489193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=489193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}